Safety and Efficacy of Travoprost/Timolol BAC-free

Inclusion Criteria: * Open-angle glaucoma or confirmed ocular hypertension. * Mean IOP in at least one eye, the same eye(s):22-36 mmHg at 9 AM on eligibility visits 1 \& 2 and 21-36 mmHg at 11 AM and 4 PM on Eligibility Visits 1 \& 2. * Sign an informed consent form. * Discontinued use of all IOP-lowering medications(s) for a minimum of 4 days to a minimum of 27 days or more prior to the Eligibility 1 Visit. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Females of childbearing potential who are pregnant, planning to become pregnant during the study period, breast-feeding, or not using adequate birth control measures. * Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component) or confirmed ocular hypertension. * History or current evidence of chronic or recurrent severe inflammatory eye disease in either eye. * History or current evidence of clinically relevant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment in either eye. * Best-corrected visual acuity (BCVA) worse than 0.6 logMAR in either eye. * Severe central visual field loss in either eye. * Not able to safely discontinue use of all IOP-lowering ocular medication(s) according to the Ocular Hypotensive Medication Washout Schedule. * History or current evidence of bronchial asthma, or severe chronic obstructive pulmonary disease (COPD) that would in the opinion of the investigator preclude the safe administration of a topical beta-blocker. * History or other evidence of severe illness or any other conditions which would make the subject, in the opinion of the investigator, unsuitable for the study. * Other protocol-defined exclusion criteria may apply.